Benitec Biopharma
BNTC
14 hedge funds and large institutions have $1.84M invested in Benitec Biopharma in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
34% more capital inflows, than outflows
Capital inflows: $1.26M | Capital outflows: $942K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
17% more funds holding
Funds holding: 12 → 14 (+2)
0.2% more ownership
Funds ownership: 7.72% → 7.92% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighPoint Advisor Group
Downers Grove,
Illinois
|
+$372K |
| 2 |
Morgan Stanley
New York
|
+$287K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$209K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$114K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$324K |
| 2 |
Two Sigma Advisers
New York
|
-$218K |
| 3 |
Two Sigma Investments
New York
|
-$171K |
| 4 |
Renaissance Technologies
New York
|
-$152K |
| 5 |
Credit Suisse
Zurich,
Switzerland
|
-$47K |
BNTC Hedge Fund Activity: Q1 2021 in Review
14 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2021, worth a combined $1.84M — up 80% from $1.02M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BNTC positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was HighPoint Advisor Group, opening a new position worth an estimated $372K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $324K sold.
- 14 institutional investors held Benitec Biopharma (BNTC) as of Q1 2021, up from 12 in Q4 2020.
- Funds reported $1.84M of Benitec Biopharma stock for Q1 2021, up 80% quarter-over-quarter.
- 8 funds opened new Benitec Biopharma positions in Q1 2021 and 6 closed out, a net change of +2 holders.
- The largest Benitec Biopharma buyer in Q1 2021 was HighPoint Advisor Group, an estimated $372K added.
- The largest Benitec Biopharma seller in Q1 2021 was Hudson Bay Capital Management, an estimated $324K sold.
Based on aggregated 13F filings for Q1 2021.